Can Vyvanse (lisdexamfetamine) cause erectile dysfunction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vyvanse and Erectile Dysfunction

Yes, Vyvanse (lisdexamfetamine) can cause erectile dysfunction, with clinical trial data showing erectile dysfunction occurring in 2.6% of adult males taking Vyvanse compared to 0% on placebo 1.

Direct Evidence from FDA Drug Label

The FDA-approved prescribing information for Vyvanse explicitly documents sexual side effects in adult males with ADHD 1:

  • Erectile dysfunction: 2.6% of males on Vyvanse vs 0% on placebo
  • Decreased libido: 1.4% of subjects on Vyvanse vs 0% on placebo

These data come from controlled 4-week clinical trials in adults with ADHD, representing the highest quality evidence directly linking Vyvanse to erectile dysfunction.

Mechanism and Context

Psychotropic drugs, including stimulants like amphetamines, can affect sexual function through multiple pathways 2. The guideline evidence indicates that most psychotropic drugs can affect libido or erectile function either through:

  • Direct pharmacologic action
  • Increasing prolactin levels
  • Decreasing testosterone levels

While the specific mechanism for lisdexamfetamine-induced erectile dysfunction is not fully elucidated, amphetamines as a class have documented effects on male sexual function 3, 4.

Clinical Significance and Management

The incidence of 2.6% represents a real but relatively modest risk that should be discussed with patients before initiating therapy. This is particularly important because:

  • Sexual dysfunction concerns can lead to medication non-adherence 5
  • Patients may be reluctant to report sexual side effects without direct questioning
  • The effect appears dose-related based on broader amphetamine literature 3

Key Clinical Considerations:

If erectile dysfunction develops on Vyvanse:

  1. Verify the temporal relationship - Did symptoms begin after starting medication or dose escalation?
  2. Rule out other contributing factors - Evaluate for cardiovascular risk factors, diabetes, hypertension, other medications, and psychological factors 2
  3. Consider dose adjustment - Lower doses may reduce sexual side effects while maintaining therapeutic benefit
  4. Evaluate for alternative ADHD medications - Non-stimulant options like atomoxetine may have different sexual side effect profiles 6

Treatment options if erectile dysfunction persists:

  • PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) are safe and effective for medication-induced erectile dysfunction and can be used concurrently with Vyvanse 7, 8
  • No contraindications exist between Vyvanse and PDE5 inhibitors (unlike nitrates which are absolutely contraindicated with PDE5 inhibitors) 8

Important Caveats

The broader amphetamine literature shows variable effects on sexual function 3:

  • Some users report enhanced sexual function (prolonged ejaculation, enhanced orgasm)
  • Others report impaired function (reduced erectile rigidity, decreased satisfaction)
  • Effects may be dose-dependent and individual-specific

Distinguish between erectile dysfunction and priapism - While rare, stimulant medications including amphetamines have been associated with priapism in case reports 6. Priapism is a medical emergency requiring immediate evaluation and discontinuation of the medication.

Documentation and Counseling

Proactively discuss sexual health with all male patients prescribed Vyvanse:

  • Document baseline sexual function before starting medication
  • Explicitly ask about sexual side effects at follow-up visits
  • Reassure patients that sexual dysfunction is a known, manageable side effect
  • Emphasize that treatment options exist and medication adjustments can be made

The 2.6% incidence from controlled trials 1 likely underestimates real-world prevalence since patients may underreport sexual symptoms without direct questioning.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.